1018946-38-7COCCCc1ccc2oc(-c3ccc(OC)c(OC)c3)cc2c1CUEPJIGXQLIOIK-UHFFFAOYSA-Nan inhibitor of beta-amyloid protein aggregation
1018946-38-7CHEMBL4066961安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
説明DWK-1339 is an inhibitor of amyloid-β (Aβ) aggregation. It inhibits aggregation of monomeric Aβ (1-42) (Aβ42) and induces disaggregation of Aβ42 fibrils in vitro when used at concentrations ranging from 3.1 to 50 μM. DWK-1339 (10 μM) reduces Aβ42-induced toxicity in HT-22 cells. In vivo, DWK-1339 (10 mg/kg) increases step-through latency in a passive avoidance test and increases spontaneous alteration in the Y-maze compared with vehicle control mice in a mouse model of Aβ42-induced acute Alzheimer''s disease. It also decreases brain levels of Aβ42 and increases spontaneous alteration in the Y-maze in the APP/PS1 transgenic mouse model of Alzheimer''s disease.
使用DWK-1339, is an orally active and blood-brain-barrier-permeable Aβ-aggregation inhibitor, used in the research of Alzheimer''s disease.
現在のフィルター条件では反応記録がありません。
読み込み中…